Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Application of MALDI-TOF Mass Spectrometry in Clinical Virology

Cristina Gómez Camarasa and Fernando Cobo
Department of Microbiology, University Hospital Virgen de las Nieves, Granada, Spain

12.1 INTRODUCTION

The matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI-TOF MS) is an analytical method of microbial identification and characterization based on the fast and precise assessment of the mass of molecules in a variable range of 100 Da–100 KDa.

The first description of the use of MS technology for bacterial identification was in 1975 [1]. Furthermore, MALDI-TOF MS was used in the mid-1990s for the identification of bacteria in research settings [2,3] but it took a long time for the introduction of this technology in routine microbiology. Then, in 2004, the first complete database for bacterial identification was reported [4].

The possibility of MALDI-TOF to quickly characterize a wide variety of microorganisms including bacteria, fungi, and viruses [5] increases its potential application in some areas of microbiological diagnosis. Thus, this technology can be used for rapid microbial identification at a relatively low cost, and it is an alternative for conventional laboratory diagnosis and molecular identification systems. The major contribution of this method is that it has drastically improved the time to identification of a positive sample.

The main use of this technology has been, until now, the identification or typing of bacteria from a positive culture. However, applications in the field of clinical virology have been also performed and are opening up new opportunities although the introduction in the routine laboratory diagnosis still remains a challenge.
In this review, MALDI-TOF technique is presented including sample preparation as well as data management and quality control, and mainly focused in viral research and diagnosis.

### 12.2 MS PRINCIPLES

The mass spectrometer is composed of three main components: an ion source to ionize and transfer sample molecules ions into a gas phase, a mass analyzer device that separate molecules depending to their mass, and finally a detector to monitor all separated ions. There are several ionization methods such as chemical ionization, electrospray, and MALDI. The choice of method basically depends to the objective of the MS analysis and the nature of the sample, although both MALDI and electrospray are techniques that permit ionization and vaporization of a big quantity of biomolecules [6].

In MS technique [7], samples are prepared by mixing several biomolecules and embedded in a matrix that will crystallize inside. The matrix is composed of small acid molecules that have a strong optical absorption in the range of the laser wavelength used, although the composition is different according to the type of laser used and the biomolecule to be analyzed. The molecules are then both desorbed and ionized by charge transfer by absorbing the energy of a short laser pulse. The desorbed and ionized molecules are first accelerated in an electrical field and ejected through a metal flight tube and collide with a detector at the end of the flight tube. This cycle is repeated at a frequency of 50 Hz or more. Thus, biomolecules are separated according to their mass and create a mass spectrum that is characterized by both the mass and the intensity of the ions. Finally, the result is a spectral signature (spike representation) that is then searched for in the appropriate database for the identification of the microorganism, comparing with values provides by the manufacturer of the database.

On the other hand, electrospray ionization mass spectrometry (ESI-MS) generally uses DNA amplicons that are dissolved in a solvent and then injected in a conductive capillary. Inside this capillary, high voltage is applied resulting in the emission of aerosols of charged drops of the sample. After this, the sample is sprayed through compartments with diminishing pressure, resulting in the formation of gas-phase multiple-charged analyte
ions, which are finally detected by the spectrometer. ESI-MS technology permits high resolution analyzing the basic composition of amplicons [8].

There are also two available methods for typing using this technology. The first method is the MALDI-resequencing that uses the iSeq method [9,10]. In this technique, RNA strands are cleaved and the products of cleavage are analyzed by MS, and their spectra are compared with the spectra of the reference sequences. Initially, MALDI-RE was used mainly for the detection of single-nucleotide polymorphisms, but currently there are additional applications for this method [11]. The second method for typing is based on the use of ESI technology to analyze specific DNA amplicons (PCR-ESI-MS) [12].

12.3 CURRENT CLINICAL VIROLOGY APPLICATIONS

12.3.1 Viral diagnosis

Viruses were traditionally detected by cell culture, which in spite of being gold standard, often took days or even weeks before any results were available. Common laboratory techniques in viruses’ detection include antibody analysis such as enzyme-linked immunosorbent assay, molecular techniques like polymerase chain reaction (PCR) and dot blot hybridization. However, MALDI-TOF technology has been already used to investigate a wide variety of viruses clinically relevant but it has advanced less as it has in bacteriology or mycology. There are several approaches of this technology for application in the field of virology.

A recent study performed a multiplex MALDI-TOF MS method that can successfully detect human herpes viruses from a wide variety of archival biological specimens [13]. The concordance rate between the MALDI-TOF MS technique and reference methods was high and the detection limits of the MS methods were comparable to the previous reports of multiplex herpes virus detection using an oligonucleotide microarray and multiplex PCR techniques. Low viral loads near the detection limit of the method and weak cross-reactivity might contribute to the few discrepant results with reference methods. Thus, this multiplex approach can be very useful for large-scale epidemiological research studies in which broad viruses detection is necessary and may also become highly useful for multiplex clinical diagnostic testing.
The rapid identification of existing and emerging respiratory viruses is crucial in combating outbreaks and epidemics. The detection of respiratory viruses such as influenza viruses are mainly performed using PCR techniques (real-time reverse transcription polymerase chain reaction; rRT-PCR) or antibody-based assays to identify the nucleoproteins. Alternative methods have been investigated for viral diagnosis, such as multiplexed flow cytometry [14], microarrays [15], and MS [16]. MS has been considered as one of the best methods for protein analysis because of its low detection limit and high accuracy. It has been also demonstrated that the combined use of antibody-magnetic nanoparticles and MALDI-TOF MS is suitable for sensitive detection of influenza viruses [17]. This method could also be used for the rapid screening of virus subtypes, suggesting a promising application in early and accurate diagnosis of influenza viruses. It has developed rapid sample preparation method to allow identification of cultured respiratory viruses with MS and multiplex PCR coupled with this technique to detect the most common respiratory viruses such as influenza virus, parainfluenza viruses, coronavirus, metapneumovirus, respiratory syncytial virus, adenovirus, and bocavirus [18–20].

Enteroviruses are also a major cause of illness in children causing gastroenteritis, hand, foot, and mouth disease and severe neurological complications such as aseptic meningitis, encephalitis, and acute neurogenic pulmonary edema. Classical detection of enteric virus is mostly based on conventional approaches such as indirect immunofluorescence assay, neutralizing testing, and cell culture and immunohistochemical detection. However, some clinical samples remain undetectable because of the absence of antibodies against viral proteins, and cell culture and neutralization tests are time-consuming and laborious. Multiplex RT-PCR and real-time PCR have shown good sensitivity and specificity [21]. For these viruses, the MALDI-TOF MS technology has demonstrated high capacity to diagnose with high throughput and short turnaround time. MALDI-TOF MS measures the intrinsic physical properties of molecules directly. A PCR mass assay combining multiplex PCR with MALDI-TOF MS technology has shown simultaneous detection of eight human enteric viruses including poliovirus, coxsackievirus A16, enterovirus 71, hepatitis E virus, echovirus, norovirus, astrovirus, and reovirus [22]. This method has a sensitivity ranging from 100 to 1000 copies per reaction and shows that this assay could be used for the simultaneous detection of co-infections with several viruses.
MALDI-TOF MS has been also used for the diagnosis of hand, foot, and mouth disease that is caused by acute enterovirus infections such as poliovirus, coxsackievirus A and B, and echovirus. These infections are clinically indistinguishable but infection with echovirus 71 could be complicated with aseptic meningitis, encephalitis, and acute flaccid paralysis. Recently, a study has developed a MALDI-TOF MS technique for the rapid diagnosis of these viruses [23]. The diagnosis of these pathogens can help to a more comprehensive surveillance of enteroviruses to understand the molecular epidemiology of enteroviruses detecting multiple genotypes simultaneously. The main advantage of this strategy is the identification of several genotypes at the same time, opening up new possibilities for the diagnosis and discovering pathological and epidemiological characteristics.

On the other hand, infection with high-risk human papillomaviruses (HPV) has been closely associated with cervical cancer as well as other types of cancer such as anus, vagina, penis, and head and neck. The diagnosis of HPV infection is based on several methods, but HPV DNA detection is necessary for the follow-up of the patients. Currently, there are three HPV assays approved for clinical use by the US Food and Drug Administration: two non-PCR-based assays (e.g., Cervista and Hologic, Marlborough, MA; Hybrid Capture 2, Qiagen, Valencia, CA) and a PCR-based method such as the Cobas HPV assay. The majority of these assays use GP5+/GP6+ consensus primers, MY09/11 primers, and their multiprimer derivatives PGMY09/11 primers and the SPF10 system. However, a new method based on the amplification of a fragment of the L1 gene region using GP5+/GP6+ consensus primers using mass array technique based on the MALDI-TOF MS technology has been recently developed to identify 14 high-risk HPVs [24–26]. This MS assay was found to be non-cross-reactive with common low-risk HPV genotypes affecting the genital tract and more sensitive (General sensitivity results ranging from 10 to 100 copies) than the Hybrid Capture 2 and conventional PCR methods. An advantage of this method is that it is possible to extend the HPV genotype spectrum by adding new type-specific primers. The use of this technique together with automated DNA extraction and PCR pipetting procedures could increase the viral detection which a decrease in the cost of the overall assay.

12.3.1.1 Diagnosis of mutations and identification of viral genotypes

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are still a major public health problem due to their worldwide morbidity and
mortality. For this reason, screening for these infections is an important part of routine laboratory activity. Serological and molecular markers are key elements for the diagnosis, prognosis, and monitoring of treatment in HBV and HCV infections. Currently, chemiluminescence assays are widely being used for viral diagnosis. Molecular techniques are routinely used for detecting, quantifying viral genomes, and analyzing their sequence to determine their genotype and detect resistance to antiviral drugs. However, MassARRAY systems based on nucleic acid analysis by MALDI-TOF MS technology provide an alternative approach to HBV and HCV genotyping [27], being accurate to identify all eight HBV genotypes. MassARRAY system generates MS patterns that are compared to sequences derived from known HBV genotypes. The main advantages of this assay are its rapidity, cost-effectiveness, and versatility. The assay produces automatic data reports and does not require any additional data interpretation.

Moreover, this method can discriminate single-point mutations and is capable of detecting wild-type and mutant alleles [28,29]. Variations in the HBV genome are biologically and clinically important and might confer drug resistance or affect virus replication capacity, resulting in failure of antiviral therapy. Some MALDI-TOF MS platforms are capable to detect 60 HBV variants with accuracy and low detection limits [29]. This technology has been used also to study the evolution of drug resistance and to detect minor HBV variants [30]. The main disadvantage of this method is that only HBV genotypes B and C were tested.

Some characteristic mutations in HBV could cause lamivudine resistance due to prolonged treatment with this antiviral agent. Current methods for detecting such variants (e.g., sequencing analysis, restriction fragment length polymorphism (RFLP), and hybridization-based assays) are time-consuming and unsuitable for screening large numbers of samples. For these reasons, it has been developed a MALDI-TOF MS assay suitable for detecting YMDD mutants [28]. This technique provides high rates of accuracy for YMDD mutations and has advantages over RFLP and direct DNA sequencing, including the ability to more sensitively and specifically detects mixed populations as well as being a simpler procedure without need for cloning or multiple PCR steps producing earlier detection of HBV mutations. Moreover, this platform is adaptable for the detection of other mutations or polymorphisms. This method will be very useful to evaluate the emergence of mutant viruses and to monitoring of antiviral treatment of chronic hepatitis B, correlating them to clinical features with regard to response to drug therapy in these patients.
On the other hand, the identification of HCV genotypes has become important to determine the clinical course and the outcome of antiviral therapy. Many HCV genotyping methods have been developed, including genotype-specific PCR, RFLP, hybridization techniques, and heteroduplex motility assays. Currently, the method of choice for this purpose is the nucleotide sequencing of a subgenomic region, but all these methods are complex to standardize, labor-intensive, or non-useful for determining multiple HCV genotypes. However, it is frequent heterogeneity during the course of infection, producing mixed-genotypes infections in some patients. Thus, researchers have developed some MALDI-TOF MS—based assays for HCV genotyping during the last years [31–33]. For genotyping purposes, MS provides accurate information on the molecular mass of the analyte and the procedure can be fully automated, as well as the direct analysis of molecules with no labels to be introduced and no separation steps followed by the image processing.

Other methods based on MALDI-TOF MS technology for viral diagnosis purposes have been also recently developed. A method based on MALDI-TOF MS technology studied the possibility of genotyping JC virus using urine samples in patients without clinical evidence of progressive multifocal leukoencephalopathy [34]. MALDI-TOF showed successfully genotype of these viruses and identifies sequence variations in the target genome. Another study used this technique to identify the possible mutations of influenza A (H5) viruses for monitoring purposes [35].

12.3.1.2 Identification of drug resistance

Finally, the application of MALDI-TOF MS technique could be useful for detecting drug resistance against some antivirals. A recent study has developed a sensitive and rapid method for the detection of ganciclovir resistance by PCR-based MALDI-TOF analysis [36].

12.3.1.3 Use of MALDI-TOF techniques in epidemiology

Other potential application of MALDI-TOF MS technology is to provide critical epidemiological data about viral infections. From an epidemiological point of view, one of the main applications of these methods is determining specific data of clinical isolates for viral diseases’ outbreaks. Because of their complexity, some viral typing techniques require specialized test methods and additional diagnostic devices. For this reason, the typing is not routinely performed in every laboratory, so these samples are being sent out of the hospital and this fact could delay the investigation of
these outbreaks and hospital-associated infections. The introduction of MALDI-TOF MS technology in the laboratories can facilitate the performing of tests leading to improve the information to the infection control staff. The introduction of MS techniques into the clinical laboratory can provide accurate and rapid epidemiological data, and it could have a critical role in hospital infection control and surveillance of viral outbreaks (Table 12.1).

### 12.4 ADVANTAGES OF MALDI-TOF MS TECHNOLOGY AND COST-EFFECTIVENESS

With regard to viral diagnosis, there are few studies comparing MALDI-TOF MS technology with other conventional based methods (e.g., viral, culture, nucleic acid–based techniques). MALDI-TOF method successfully detects viruses in a wide variety of biological specimens, and the concordance rate between MALDI-TOF and these techniques is high. PCR–based identification strategies have some limitations such as much longer turnaround time than MS, reagent and labor costs, and some technical problems. On the other hand, MALDI-TOF technology can also be used to identify viruses in co-infected samples. These methods are capable of simultaneous detection of multiple pathogens in a single assay and can then prevent misdiagnosis and delays in treatment without increasing costs or adding a new step to the process.

With regard to the technical problems, PCR methods could have inhibitory particles and issues of contamination; thus, separate areas for sample preparation, amplification, and analysis are needed. Furthermore, nucleic acid–based techniques are expensive and time-consuming and appear in most cases less convenient than MS for routine laboratory identifications. For MALDI-TOF there must be significant progress made in

| Applications                                      |
|--------------------------------------------------|
| Identification of viruses from clinical samples  |
| Diagnosis of mutations for viruses               |
| Screening of viral subtypes                      |
| Identification of antiviral resistance           |
| Epidemiology of viral infections                 |

Table 12.1 Summary of the main applications of MALDI-TOF MS to clinical virology
closing the upfront of PCR processing to include DNA extraction and
the PCR process itself.

MALDI-TOF MS methods also allow large-scale research studies not
only for fresh samples but also on archival samples from several biological
specimens.

The main advantages and disadvantages of MALDI-TOF MS technol-
ogy are shown in Table 12.2.

The most remarkable differences between MALDI-TOF method and
other conventional techniques are the estimated time and costs required
for sample identification. There are no studies of cost-effectiveness in
viruses, but it is estimated that the cost of bacterial identification repre-
sents only 17%—32% of the costs of conventional identification methods
[37]. Other studies have shown that the cost of reagents required for phe-
notypic and nucleic acid identification is higher than for MS techniques
[38]. The expensive cost of MALDI-TOF devices is comparable with
other laboratory equipment. Moreover, MALDI-TOF is a rapid tech-
nique if compared with other methods, so this technology improves the
working time (e.g., preanalytical procedure) as well as the turnaround
time (e.g., analytical procedure). The time needed for microorganism
identification is <15 minutes for MS method, whereas conventional
techniques need 5—48 hours.

One of the main weaknesses of MALDI-TOF is that the identification
is limited by database. The mass profile is used as a mass spectrum to
compare with those of well-characterized organisms in a database. The
spectrum typically includes specific peaks, so that with a comprehensive
library of spectra, the identification might be performed by using
bioinformatics.

| Advantages                                      | Disadvantages                                      |
|------------------------------------------------|---------------------------------------------------|
| Characterization of a wide variety of viruses  | Identification limited by database for sequencing of genetic markers: |
| Reliable and rapid identification              | • Time-consuming                                   |
| Accurate and sensitive method                  | • High cost                                        |
| High throughput                                | • Different genetic markers                        |
| Easy sample preparation                        |                                                   |
| Cost-effective                                 |                                                   |
| Improve the patient management                 |                                                   |
| Automation possible                            |                                                   |
Currently, there are a wide number of references in the database from the available commercial platforms for MALDI-TOF techniques. These mass spectra can establish the comparison and further identification of microorganisms, but until now these spectra are limited. The database will expand due to the collaboration between commercial companies and the hospitals of several countries, so the available databases should be improved in the near future. The comparison of data from different companies’ instruments will be very important, but this fact is currently not feasible.

12.5 DATA MANAGEMENT AND QUALITY CONTROL

Sample preparation by MALDI-TOF MS remains laborious today, although some robots are being developed to improve the deposit of the sample and the matrix on the target. Moreover, some aspects of MALDI-TOF MS technology are being also investigated; for example, the laser pulse frequency, disposable target slides, and the mass spectrometers as well as the software used for the communication between laboratory equipment and laboratory information systems (LIS).

Data management primarily depends on the interpretation of crude data. Currently, some methods for data interpretation have been investigated [39]. An important fact is the integration of information communication systems to physicians that requires hospital information systems or LIS.

Reference databases require an update if new information is obtained. The addition of new isolates or mutations could improve this tool and the final diagnosis of the diseases. A robust system of information for regional prevalence of infectious diseases, emerging and reemerging infectious pathogens, the discovery of new mutations, and local or pandemic changes in epidemiology is necessary.

The MALDI-TOF MS system is increasingly used in clinical diagnostic laboratory for viral identification, mutation analysis, genotyping, and antiviral resistance studies. However, there are still some problems arising during sample extraction affecting to the extraction protocol and to the adequate reagent conservation for the assay. These problems could be avoided by the introduction of an adequate quality control program. The extraction step should be daily checked by training technicians as well as the introduction of routinely internal quality controls.
Other aspect of this technique that must be submitted to an adequate quality control is the deposit of the sample on the microplate and the cleaning of this microplate. It is necessary to implement a control about these issues for the correct identification of the samples.

Finally, it is a good practice for these devices to have the adequate maintenance of the MALDI-TOF based on a global quality control program. In this sense, the calibration control is a tool useful to recalibrate the spectrometer device and to identify technical problems. Appropriate maintenance of these devices is essential to carry out an adequate and accurate viral identification.

It is essential for both to continuously improve the quality of the database and to introduce a quality control program for the MS device. The implementation of these programs can help to improve the quality of the overall procedure, so it will be the basis to improve the usefulness and the accuracy of MALDI-TOF.

12.6 CONCLUDING REMARKS

MALDI-TOF MS is a relatively recent innovation for the identification of microorganisms and is being used in many clinical microbiology laboratories. The main application of this technology is, at the moment, the identification of bacteria to species level in less than a minute, although this method is about to become the standard of identification of microorganisms in most laboratories.

MALDI-TOF MS technology is also being introduced in virology assays. The main applications in this field are the identification of viruses from clinical samples, the discovery of mutations for these viruses, the rapid screening of virus subtypes, its use in molecular epidemiology, and the detection of resistance to several antiviral agents.

Future applications of MALDI-TOF MS in clinical virology will be developed to provide more accurate identification on clinical specimens and will include the detection of resistant protein markers and specific virulence for several viruses. However, the introduction of this technology routinely for virology diagnosis would enable a change in working practices. Moreover, this fact will require a complete integration into laboratory workflow and several technical improvements such as the detection of
sensitivity. The continuous update of databases for microorganisms will be also an important issue, as well as the possibility for the diagnosis directly from clinical samples.

MS methods can be currently used for viral diagnosis but refinement of technology will be an important approach for the introduction of MALDI-TOF in routine viral diagnosis.

REFERENCES

[1] Anhalt JP, Fenselau C. Identification of bacteria using mass spectrometry. Anal Chem 1975;47:219–25.

[2] Claydon MA, Davey SN, Edwards-Jones V, Gordon DB. The rapid identification of intact microorganisms using mass spectrometry. Nat Biotechnol 1996;14:1584–6.

[3] Holland RD, Wilkes JG, Rafii F. Rapid identification of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1996;10:12227–32.

[4] Keys CJ, Dare DJ, Sutton H. Compilation of a MALDI-TOF mass spectral database for the rapid screening and characterisation of bacteria implicated in human infectious diseases. Infect Genet Evol 2004;4:221–42.

[5] Giebel R, Worden C, Rust SM. Microbial fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) applications and challenges. Adv Appl Microbiol 2010;71:149–84.

[6] Emonet S, Shah HN, Cherkauui A, Schrenzel J. Application and use of various mass spectrometry methods in clinical microbiology. Clin Microbiol Infect 2010;16:1604–13.

[7] Van Belkum A, Welker M, Erhard M, Chatellier S. Biomedical mass spectrometry in today’s and tomorrow’s clinical microbiology laboratories. J Clin Microbiol 2012;50:1513–17.

[8] Ecker DJ, Sampath R, Massire C. Ibis T5000: a universal biosensor approach for microbiology. Nat Rev Microbiol 2008;6:553–8.

[9] Stanssens P, Zabeau M, Meersseman G. High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res 2004;14:126–33.

[10] Honisch C, Chen Y, Mortimer C. Automated comparative sequence analysis by base-specific cleavage and mass spectrometry for nucleic acid-based microbial typing. Proc Natl Acad Sci USA 2007;104:10649–54.

[11] Honisch C, Chen Y, Hillenkamp F. Comparative DNA sequence analysis and typing using mass spectrometry. In: Sha HN, Gharbia SE, editors. Mass spectrometry for microbial proteomics. Chichester: John Wiley&Sons; 2010. p. 443–62.

[12] Ecker DJ, Massire C, Blyn LB. Molecular genotyping of microbes by multilocus PCR and mass spectrometry: a new tool for hospital infection control and public health surveillance. Methods Mol Biol 2009;551:71–87.

[13] Sjöholm MIL, Dillner J, Carlson J. Multiplex detection of human herpes viruses from archival specimens by using matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol 2008;46:540–5.

[14] Yan X, Zhong W, Tang A, Schielke EG, Hang W, Nolan JP. Multiplexed flow cytometry immunoassay for influenza virus detection and differentiation. Anal Chem 2005;77:7673–8.

[15] Townsend MB, Dawson ED, Mehlmann M. Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. J Clin Microbiol 2006;44:2863–71.
[16] Downard KM, Morrissey B, Schwahn AB. Mass spectrometry analysis of the influenza virus. Mass Spect Rev 2009;28:35–49.

[17] Chou TC, Hsu W, Wang CH, Chen YJ, Fang JM. Rapid and specific influenza virus detection by functionalized magnetic nanoparticles and mass spectrometry. J Nanotechnol 2011;9:52.

[18] Majchrzykiewicz-Koehorst JA, Heikens E, Trip H, Hulst AG, de Jong AL, Viveen MC, et al. Rapid and generic identification of influenza A and other respiratory viruses with mass spectrometry. J Virol Methods 2015;213:75–83.

[19] Zhang C, Xiao Y, Du J, Ren L, Wang J, Peng J, et al. Application of multiplex PCR coupled with matrix-assisted laser desorption ionization-time of flight analysis for simultaneous detection of 21 common respiratory viruses. J Clin Microbiol 2015;53:2549–54.

[20] Xiu L, Zhang C, Wu Z, Peng J. Establishment and application of a universal coronavirus screening method using MALDI-TOF mass spectrometry. Front Microbiol 2017;8:1510.

[21] Thao NTT, Ngoc NTK, Tu PV. Development of a multiplex polymerase chain reaction assay for simultaneous identification of human enterovirus 71 and coxsackievirus A16. J Viral Methods 2010;170:134–9.

[22] Piao J, Jiang J, Xu B. Simultaneous detection and identification of enteric viruses by PCR-mass assay. PLoS One 2012;7:e42251.

[23] Peng J, Yang F, Xiong Z. Sensitive and rapid detection of viruses associated with hand foot and mouth disease using multiplexed MALDI-TOF analysis. J Clin Virol 2013;56:170–4.

[24] Yi X, Li J, Yu S. A new PCR-based mass spectrometry system for high-risk HPV. Part I. Am J Clin Pathol 2011;136:913–19.

[25] Duu H, Yi J, Wu R. A new PCR-based mass spectrometry system for high risk HPV. Part II. Am J Clin Pathol 2011;136:920–3.

[26] Cricca M, Marasco E, Alessandrini F, Fazio C, Prossomariti A, Savini C, et al. High-throughput genotyping of high-risk human papillomavirus by MALDI-TOF mass spectrometry-based method. New Microbiol 2015;38:211–23.

[27] Ganova-Raeva L, Ramachandran S, Honisch C. Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol 2010;48:4161–8.

[28] Hong SP, Kim NK, Hwang SG. Detection of hepatitis B virus YMDD variants using mass spectrometry analysis of oligonucleotide fragments. J Hepatol 2004;40:837–44.

[29] Luan J, Yuan J, Li X. Multiplex detection of 60 hepatitis B virus variants by MALDI-TOF mass spectrometry. Clin Chem 2009;55:1503–9.

[30] Rybicka M, Stalke P, Bielawski KP. Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS. Clin Microbiol Infect 2015;21:288.

[31] Kim YJ, Kim SO, Chung HJ. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin Chem 2005;51:1123–31.

[32] Ilina EN, Malakhova MV, Generozov EV, Nikolaev EN, Govorun VM. Matrix-assisted laser desorption ionization-time of flight (mass spectrometry) for hepatitis C virus genotyping. J Clin Microbiol 2005;43:2810–15.

[33] Oh HB, Kim SO, Cha CH. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5’ untranslated region using a matrix assisted laser desorption/ ionization time of flight-based assay restriction fragment mass polymorphism. J Med Virol 2008;80:1712–19.

[34] Bayliss J, Moser R, Bowden S, McLean CA. Characterisation of single nucleotide polymorphisms in the genome of JC polyomavirus using MALDI TOF mass spectrometry. J Virol Methods 2010;164:63–7.
[35] Yea C, McCorrister S, Westmacott G, Petric M, Tellier R. Early detection of influenza A (H5) viruses with affinity for the human sialic acid receptor by MALDI-TOF mass spectrometry based mutation detection. J Virol Methods 2011;172:72–7.

[36] Zürcher S, Mooser C, Lüthi AU. Sensitive and rapid detection of ganciclovir resistance by PCR based MALDI-TOF analysis. J Clin Virol 2012;54:359–63.

[37] Seng P, Drancourt M, Gouriet F. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009;49:543–51.

[38] Cherkaoui A, Hibbs J, Emonet S. Comparison of two matrix-assisted laser desorption ionization-time of flight mass spectrometry methods with conventional phenotypic identification for routine identification of bacteria to the species level. J Clin Microbiol 2010;48:1169–75.

[39] Welker M. Proteomics for routine identification of microorganisms. Proteomics 2011;11:3143–53.